Sustained high levels of serum HHV-8 DNA years before multicentric Castleman's disease despite full suppression of HIV with highly active antiretroviral therapy [1]

AIDS

Volumn 17, Issue 9, 2003, Pages 1407-1408

  De Jong, Rianne Baatenburg ^a   Kluin, Philip M ^a   Rosati, Stefano ^a   Van Haelst, Paul I ^a   Sprenger, Herman G ^a   Van Spronsen, Dick Johan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; IMMUNOGLOBULIN G; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PREDNISOLONE; STAVUDINE; VIRUS DNA; VIRUS RNA;

ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; CASE REPORT; DISEASE ASSOCIATION; DISEASE COURSE; ERYTHROCYTE TRANSFUSION; HEMOLYTIC ANEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; KAPOSI SARCOMA; LETTER; LEUKOCYTE COUNT; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS INFECTION; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; FATAL OUTCOME; GIANT LYMPH NODE HYPERPLASIA; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; VIRAL LOAD;

EID: 0038675407     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200306130-00022     Document Type: Letter

References (11)

1. Oksenhendler E, Carcelain G, Aoki Y, Boulanger E, Maillard A, Clauvel JP, Agbalika F. High levels of human herpesvirus-8 viral load, human interleukin-6, interleukin-10 and C-reactive protein correlates with exacerbation of Multicentric Castleman disease in HIV infected patients. Blood 2000; 15:2069-2073.
2. Zietz C, Bogner, JR, Goebel FD, Loehrs U. An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS. N Engl J Med 1999; 340:1923-1924.
3. Lanzafame M, Caretta G, Trevenzoli M, Lazzarini L, Vento Ercole Concia S. Successful treatment of Castleman's disease with HAART in two HIV infected patients. J Infect Dis 2000; 40: 90-91.
4. Oksenhendler E, Duarte M, Soulier J, Cacoub P, Welker Y, Cadranel J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 1996; 10:61-67.
5. Oksenhendler E, Boulanger E, Galicier, Du MQ, Dupin N, Diss TC, et al. High incidence of Kaposi's sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and Multicentric Castleman's disease. Blood 2002; 99:2331-2236.
6. Du MQ, Liu H, Diss TC, Ye H, Hamoudi RA, Dupin N, et al. Kaposi's sarcoma associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman's disease associated lymphoproliferative disorders. Blood 2001; 97:2130-2136.
7. Scott D, Cabral L, Harrington WJ Jr. Treatment of HIV-associated multicentric Castleman's disease with oral etoposide. Am J Hematol 2001; 66:148-150.
8. Corbellino M, Bestetti G, Scalamogna C, Calattini S, Galazzi M, Meroni L, et al. Long-term remission of Kaposi's sarcoma-associated herpesvirus-related multicentric Castleman's disease with anti-CD20 monoclonal antibody therapy. Blood 2001; 98:3473-3475.
9. Boivin G, Gaudreau A, Routy JP. Evaluation of the human herpesvirus 8 DNA load in blood and Kaposi's sarcoma skin lesion from AIDS patients on highly active antiretroviral therapy. AIDS 2000; 14:1907-1910.
10. Lebbé C, Blum L, Pellet C, Blanchard G, Verola O, Morel P, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998; 12:F45-F49.
11. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Updated 4 February 2002. http://www.aidsinfo.nih.gov.